12:00 AM
 | 
Jul 26, 2004
 |  BioCentury  |  Product Development

Different strokes for AGY

AGY Therapeutics Inc.'s deal with M's Science Corp. gets AGY into the clinic, but in an indication where many others have broken their picks: stroke.

AGY is taking a different tack, and plans to develop its newly acquired AGY-94806 sigma receptor agonist to improve functional recovery in stroke patients rather than treating the stroke while it's occurring. But while the company is side-stepping the relatively small window for treating stroke, improving functional recovery is essentially uncharted waters - there are no FDA approved drugs for the indication and AGY essentially must blaze a trail through the clinic.

AGY said the...

Read the full 501 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >